Keros Therapeutics Appoints Jean-Jacques Bienaimé to its Board of Directors

Company Overview - Keros Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics targeting disorders linked to dysfunctional signaling of the TGF-ß family of proteins [1][4] - The company is recognized as a leader in understanding the TGF-ß family of proteins, which are crucial for the growth, repair, and maintenance of various tissues [4] Recent Developments - Keros announced the appointment of Jean-Jacques Bienaimé to its Board of Directors, effective June 1, 2024 [1] - The CEO, Jasbir Seehra, expressed confidence in Bienaimé's extensive experience in biotechnology and pharmaceuticals, which will be beneficial for the company's growth and product pipeline [2] Leadership Background - Jean-Jacques Bienaimé previously served as CEO of BioMarin Pharmaceutical Inc. from May 2005 until his retirement in December 2023 [2] - He has held leadership roles at Genencor, Inc. and Sangstat Medical Corporation, and has experience in senior management at Rhône-Poulenc Rorer Pharmaceuticals [2] - Bienaimé holds an M.B.A. from the Wharton School and a degree in economics from the École Supérieure de Commerce de Paris [3] Product Pipeline - Keros' lead product candidate, KER-050 (elritercept), targets low blood cell counts, including anemia and thrombocytopenia, in patients with MDS and myelofibrosis [4] - The second candidate, KER-012 (cibotercept), is aimed at treating pulmonary arterial hypertension and cardiovascular disorders [4] - KER-065 is being developed for obesity and neuromuscular diseases [4]